Company research
PURE BIOSCIENCE, INC.
CIK 1006028Updated Oct 30, 2026
SecurityPURE · OTC · equity
Name history
PURE BIOSCIENCE · through Mar 17, 2011INNOVATIVE MEDICAL SERVICES · through Sep 2, 2003
PURE price & chart
Loading TradingView…
OTC:PURE on TradingView ↗In the news
Purecore Strengthens Technical Advisory Expertise with Nuclear Fuel Cycle and Uranium Enrichment Specialist, Ted Rygas, PhD ↗
Purecore Metals Announces Field Program Commencement at the Bankier Property ↗
Purecore Metals Inc. Announces Listing on the Canadian Securities Exchange Under the Symbol “PURE” ↗
Recent filings
10-K filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,558,000Source | 1,057,000Source | 920,000Source | 788,000Source | 574,000Source | 1,086,000Source | 1,186,000Source | 924,000Source | 1,058,000Source | 818,000Source | 1,825,000Source | 4,484,000Source |
| Property, Plant and Equipment, NetUSD | 9,000Source | 11,000Source | 51,000Source | 9,000Source | 12,000Source | 147,000Source | 10,000Source | 13,000Source | 11,000Source | 13,000Source | 221,000Source | 620,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 983,000Source | 540,000Source | 442,000Source | 198,000Source | 202,000Source | 557,000Source | 434,000Source | 346,000Source | 334,000Source | 349,000Source | 1,095,000Source | 3,391,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 242,000Source | 287,000Source | 234,000Source | 252,000Source | 180,000Source | 171,000Source | 389,000Source | 371,000Source | 474,000Source | 298,000Source | 285,000Source | 201,000Source |
| Inventory, NetUSD | 232,000Source | 131,000Source | 74,000Source | 244,000Source | 75,000Source | 74,000Source | 237,000Source | 72,000Source | 141,000Source | 56,000Source | 88,000Source | 179,000Source |
| Assets, CurrentUSD | 1,549,000Source | 1,046,000Source | 869,000Source | 779,000Source | 562,000Source | 939,000Source | 1,176,000Source | 911,000Source | 1,047,000Source | 805,000Source | 1,604,000Source | 3,864,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,397,000Source | 5,871,000Source | 3,066,000Source | 7,061,000Source | 4,841,000Source | 2,407,000Source | 6,732,000Source | 4,420,000Source | 6,174,000Source | 3,682,000Source | 1,553,000Source | 575,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,301,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,119,000Source | 1,114,000Source |
| Additional Paid in CapitalUSD | 133,727,000Source | 132,729,000Source | 132,574,000Source | 132,851,000Source | 132,696,000Source | 132,542,000Source | 132,793,000Source | 132,669,000Source | 132,759,000Source | 132,612,000Source | 132,398,000Source | 132,079,000Source |
| Retained Earnings (Accumulated Deficit)USD | -140,867,000Source | -138,662,000Source | -135,839,000Source | -140,243,000Source | -138,082,000Source | -134,982,000Source | -139,458,000Source | -137,284,000Source | -138,994,000Source | -136,595,000Source | -133,245,000Source | -129,284,000Source |
| Stockholders' Equity Attributable to ParentUSD | -5,839,000Source | -4,814,000Source | -2,146,000Source | -6,273,000Source | -4,267,000Source | -1,321,000Source | -5,546,000Source | -3,496,000Source | -5,116,000Source | -2,864,000Source | 272,000Source | 3,909,000Source |
| Liabilities and EquityUSD | 1,558,000Source | 1,057,000Source | 920,000Source | 788,000Source | 574,000Source | 1,086,000Source | 1,186,000Source | 924,000Source | 1,058,000Source | 818,000Source | 1,825,000Source | 4,484,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,654,000Source | 972,000Source | 666,000Source | 3,055,000Source | 866,000Source | 545,000Source | 3,159,000Source | 911,000Source | 938,000Source | 733,000Source | 532,000Source | 575,000Source |
| Accounts Payable, CurrentUSD | 719,000Source | 799,000Source | 506,000Source | 767,000Source | 700,000Source | 409,000Source | 879,000Source | 718,000Source | 784,000Source | 601,000Source | 422,000Source | 488,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 181,000Source | 173,000Source | 160,000Source | 149,000Source | 166,000Source | 136,000Source | 176,000Source | 193,000Source | 154,000Source | 132,000Source | 110,000Source | 87,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortizationUSD | — | — | — | — | — | — | — | — | 2,000Source | 148,000Source | 117,000Source | 213,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 55,000Source | 33,000Source | 58,000Source | 27,000Source | 34,000Source | 57,000Source | 147,000Source | 214,000Source | 324,000Source | 567,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -85,000Source | 73,000Source | 176,000Source | 13,000Source | 84,000Source | -167,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 96,000Source | 16,000Source | 85,000Source | -32,000Source | -57,000Source | -78,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -250,000Source | -503,000Source | -2,015,000Source | -2,531,000Source | -3,278,000Source | -2,418,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | -33,000Source | -81,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 33,000Source | 81,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 350,000Source | 500,000Source | 2,000,000Source | 1,785,000Source | 1,015,000Source | 3,500,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 100,000Source | -3,000Source | -15,000Source | -746,000Source | -2,296,000Source | 1,001,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,058,000Source | 615,000Source | 273,000Source | 277,000Source | 509,000Source | 421,000Source | 409,000Source | 424,000Source | 1,170,000Source | 3,466,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 3,000Source | 5,000Source | 5,000Source | 2,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 34,000Source | 57,000Source | 144,000Source | 214,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 1,000Source | — | 2,000Source | 148,000Source | 117,000Source | 146,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | 239,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 239,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 299,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,650Source | 1,650Source |
| InterestExpenseNonoperatingUSD | — | — | 106,000Source | 78,000Source | 101,000Source | 70,000Source | 94,000Source | 62,000Source | 299,000Source | 155,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | 34,000Source | 75,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -624,000Source | -580,000Source | -785,000Source | -798,000Source | -464,000Source | -689,000Source | -2,399,000Source | -3,350,000Source | -3,961,000Source | -3,491,000Source |
| Nonoperating Income (Expense)USD | — | — | -106,000Source | 4,000Source | -102,000Source | -73,000Source | -85,000Source | -62,000Source | -127,000Source | -159,000Source | -18,000Source | 233,000Source |
| Operating ExpensesUSD | — | — | 787,000Source | 867,000Source | 921,000Source | 952,000Source | 829,000Source | 952,000Source | 3,575,000Source | 4,343,000Source | 4,914,000Source | 4,724,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 82,000Source | -1,000Source | -3,000Source | 9,000Source | — | 172,000Source | -4,000Source | -4,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 3,500,000Source |
| General and Administrative Expense | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 506,000Source | 491,000Source | 444,000Source | 391,000Source | 708,000Source | 556,000Source | 2,202,000Source | 1,963,000Source | 1,877,000Source | 1,853,000Source |
| Cost of RevenueUSD | — | — | 237,000Source | 208,000Source | 206,000Source | 164,000Source | 258,000Source | 231,000Source | 899,000Source | 811,000Source | 906,000Source | 853,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 708,000Source | 776,000Source | 847,000Source | 871,000Source | 743,000Source | 881,000Source | 3,259,000Source | 3,981,000Source | 4,302,000Source | 4,106,000Source |
| Operating Income (Loss)USD | — | — | -518,000Source | -584,000Source | -683,000Source | -725,000Source | -379,000Source | -627,000Source | -2,272,000Source | -3,191,000Source | -3,943,000Source | -3,724,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 82,000Source | -1,000Source | -3,000Source | 9,000Source | — | 172,000Source | -4,000Source | -4,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,650Source | 1,650Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -624,000Source | -580,000Source | -785,000Source | -798,000Source | -464,000Source | -689,000Source | -2,399,000Source | -3,350,000Source | -3,961,000Source | -3,491,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.01Source | -0.01Source | -0.01Source | -0.01Source | 0Source | -0.01Source | -0.02Source | -0.03Source | -0.04Source | -0.04Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.01Source | -0.01Source | -0.01Source | -0.01Source | 0Source | -0.01Source | -0.02Source | -0.03Source | -0.04Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 110,833,042Source | 111,856,473Source | 111,886,473Source | 111,856,473Source | 111,886,473Source | 111,856,473Source | 111,862,884Source | 111,856,473Source | 111,404,418Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 110,833,042Source | 111,856,473Source | 111,886,473Source | 111,856,473Source | 111,886,473Source | 111,856,473Source | 111,862,884Source | 111,856,473Source | 111,404,418Source | — |
| Interest Expense (non-operating)USD | — | — | 106,000Source | 78,000Source | 101,000Source | 70,000Source | 94,000Source | 62,000Source | 299,000Source | 155,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 2,000Source | 148,000Source | 117,000Source | 213,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | 239,000Source |
| Gross ProfitUSD | — | — | 269,000Source | 283,000Source | 238,000Source | 227,000Source | 450,000Source | 325,000Source | 1,303,000Source | 1,152,000Source | 971,000Source | 1,000,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 14,000Source | 6,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | 91,000Source | 60,000Source | 287,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -106,000Source | 4,000Source | -102,000Source | -73,000Source | -85,000Source | -62,000Source | -127,000Source | -159,000Source | -18,000Source | 233,000Source |
| Operating ExpensesUSD | — | — | 787,000Source | 867,000Source | 921,000Source | 952,000Source | 829,000Source | 952,000Source | 3,575,000Source | 4,343,000Source | 4,914,000Source | 4,724,000Source |
| Research and Development ExpenseUSD | — | — | 79,000Source | 91,000Source | 74,000Source | 81,000Source | 86,000Source | 71,000Source | 316,000Source | 302,000Source | 297,000Source | 319,000Source |
| General and Administrative Expense | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
Filing attachments
ex4-1.htm · 10-K · 2026-10-29
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws. The summary does not purport to be complete and is qualified in its entirety by reference to our Certificate of In…
Read attachment ↗ex4-5.htm · 10-K · 2026-10-29
Exhibit 4.5 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT. CONVERT…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-29
Exhibit 99. 1 PURE Bioscience Reports Fiscal 2026 Financial Results El CAJON, CA - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company,” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal year ended July 31, 2026. Summary of Results - Year-End Operations Net product sales were $2,315,000 and $2,198,000 for the fiscal years ended July 31, 2026 and 2025, respectively. The $117,000 increase …
Read attachment ↗ex99-1.htm · 8-K · 2026-06-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results EL CAJON, Calif. - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2026. Summary of Results of Operations - Third Quarter Net product sales were $506,000 and $489,000 for the fiscal third quart…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results EL CAJON, Calif. - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2026. Summary of Results - Fiscal Second Quarter Operations Net product sales were $443,000 and $391,000 for the fiscal se…
Read attachment ↗ex99-1.htm · 8-K · 2025-12-15
EX-99.1 2 ex99-1.htm EX-99.1 PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results EL CAJON, Calif. - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2025. Summary of Results of Operations - Fiscal First Quarter Net product sales were $707,000 and $555,000 for the fiscal first quarter en…
Read attachment ↗